$Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab$

Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab

Blinatumomab has demonstrated significant efficacy in adult and pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-cell ALL) and patients with measurable residual disease (MRD). This review aimed to compare median relapse-free survival (RFS) and median overall sur...

Full description

Bibliographic Details
Main Authors:	Hagop M. Kantarjian, Aaron C. Logan, Faraz Zaman, Nicola Gökbuget, Ralf C. Bargou, Yi Zeng, Gerhard Zugmaier, Franco Locatelli
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-10-01
Series:	Therapeutic Advances in Hematology
Online Access:	https://doi.org/10.1177/20406207231201454

Similar Items

Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
by: Hagop M. Kantarjian, et al.
Published: (2021-11-01)

Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis
by: Max S. Topp, et al.
Published: (2021-04-01)

Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study
by: Franco Locatelli, et al.
Published: (2021-10-01)

Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study
by: Franco Locatelli, et al.
Published: (2021-02-01)

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
by: Jiao Xie, et al.
Published: (2023-08-01)

Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date
by: Hathaway L, et al.
Published: (2018-10-01)

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL
by: Virginie Nägele, et al.
Published: (2017-05-01)

P359: IMPROVED OVERALL SURVIVAL AND MRD CLEARANCE WITH BLINATUMOMAB VS CHEMOTHERAPY AS PRE-TRANSPLANT CONSOLIDATION IN PEDIATRIC HIGH-RISK FIRST-RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
by: F. Locatelli, et al.
Published: (2022-06-01)

Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
by: Tomoaki Ueda, et al.
Published: (2022-01-01)

Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia
by: Katarzyna Pawinska-Wasikowska, et al.
Published: (2022-01-01)

P372: DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB
by: W. Macaron, et al.
Published: (2022-06-01)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
by: Jeanne Bohler, et al.
Published: (2022-12-01)

Efficacy and safety of blinatumomab in children with relapsed/refractory B cell acute lymphoblastic leukemia: A systematic review and meta-analysis
by: Bin Chen, et al.
Published: (2023-01-01)

P379: PONATINIB AND BLINATUMOMAB IN RELAPSED/REFRACTORY PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR CHRONIC MYELOID LEUKEMIA IN LYMPHOID BLAST PHASE: SUBGROUP ANALYSIS FROM A PHASE II TRIAL
by: Fadi Haddad, et al.
Published: (2023-08-01)

Blinatumomab therapy for B cell acute lymphoblastic leukemia accompanied by persistent or relapsed low-level MRD prior to hematopoietic stem cell transplantation in Chinese children: a case series
by: Guichi Zhou, et al.
Published: (2023-02-01)

S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL
by: Fadi Haddad, et al.
Published: (2023-08-01)

Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study
by: Nicola Stefano Fracchiolla, et al.
Published: (2023-09-01)

S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910
by: Mark Litzow, et al.
Published: (2023-08-01)

P1736: CHARACTERISTICS, HEALTHCARE UTILIZATION, AND COSTS ASSOCIATED WITH INOTUZUMAB OZOGAMICIN, BLINATUMOMAB, OR OTHER AGENTS FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
by: A. Russell-Smith, et al.
Published: (2022-06-01)

Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study
by: Hongsheng Zhou, et al.
Published: (2022-12-01)

P361: HIGH REMISSION AND SURVIVAL RATE IN ADULTS WITH MINIMAL RESIDUAL DISEASE-POSITIVE OR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA TREATED WITH BLINATUMOMAB IN ROUTINE CLINICAL PRACTICE
by: Sabina Chiaretti, et al.
Published: (2023-08-01)

Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
by: Massimiliano Bonifacio, et al.
Published: (2022-01-01)

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
by: Le Jeune C, et al.
Published: (2016-02-01)

Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study
by: Songmi Wang, et al.
Published: (2023-01-01)

Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting
by: Alexander Russell-Smith, et al.
Published: (2023-12-01)

Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study
by: Nicolas Boissel, et al.
Published: (2023-01-01)

Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
by: Lee KJ, et al.
Published: (2016-08-01)

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
by: Hagop Kantarjian, et al.
Published: (2023-05-01)

Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment
by: Hoda Pourhassan, et al.
Published: (2023-08-01)

Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia
by: Portell CA, et al.
Published: (2013-04-01)

Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score–matched cohort analysis
by: Jae-Ho Yoon, et al.
Published: (2023-03-01)

Case report: Donor lymphocyte infusion and blinatumomab as treatment for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation
by: Flavia Antonucci, et al.
Published: (2024-03-01)

Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study
by: Houli Zhao, et al.
Published: (2020-05-01)

Successful treatment with blinatumomab for acute lymphoblastic leukemia in an older adult patient complicated with hepatocarcinoma
by: Masuho Saburi, et al.
Published: (2024-01-01)

Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib- based chemotherapy
by: Zhao J, et al.
Published: (2015-06-01)

Blinatumomab therapy in a relapsed acute lymphoblastic leukemia with isolated radius involvement following allogeneic bone marrow transplant: a case report
by: İbrahim Halil Açar, et al.
Published: (2020-10-01)

Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario
by: Anne Tierens, et al.
Published: (2021-03-01)

Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy
by: Francesco Paolo Tambaro, et al.
Published: (2020-09-01)

Long-Term Follow up of Blinatumomab in Older Patients with B-Cell Acute Lymphoblastic Leukemia
by: Yamini K. Kathari, et al.
Published: (2024-03-01)

Bone marrow necrosis after treatment with blinatumomab for acute lymphoblastic leukemia: A case report
by: Ruihua Mi, et al.
Published: (2024-03-01)